Subclinical vasculitis as a potential mechanism to explain the heightened cardiovascular risk in rheumatoid arthritis

Circulation

Volumn 126, Issue 21, 2012, Pages 2449-2451

  Fayad, Zahi A ^a   Greenberg, Jeffrey D ^b   Bucerius, Jan ^c,d,e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NYU HOSPITAL FOR JOINT DISEASES   (United States)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; AUTOIMMUNITY; CARDIOVASCULAR RISK; EDITORIAL; HEART INFARCTION; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; VASCULITIS;

AORTA; AORTA, THORACIC; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR STIFFNESS; VASCULITIS;

EID: 84869868291     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.146092     Document Type: Editorial

References (27)

1. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, Johnstroóm P, Davenport AP, Kirkpatrick PJ, Arch BN, Pickard JD, Weissberg PL. Imaging atherosclerotic plaque inflammation with [18F]- fluorodeoxyglucose positron emission tomography. Circulation. 2002; 105:2708 -2711. (Pubitemid 34615139)
2. Yun M, Yeh D, Araujo LI, Jang S, Newberg A, Alavi A. F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med. 2001;26: 314-319. (Pubitemid 32226294)
3. Myers KS, Rudd JH, Hailman EP, Bolognese JA, Burke J, Pinto CA, Klimas M, Hargreaves R, Dansky HM, Fayad ZA. Correlation between arterial FDG uptake and biomarkers in peripheral artery disease. J Am Coll Cardiol Cardiovasc Imaging. 2012;5:38-45.
4. Bucerius J, Duivenvoorden R, Mani V, Moncrieff C, Rudd JH, Calcagno C, Machac J, Fuster V, Farkouh ME, Fayad ZA. Prevalence and risk factors of carotid vessel wall inflammation in coronary artery disease patients: FDG-PET and CT imaging study. J Am Coll Cardiol Cardiovasc Imaging. 2011;4:1195-1205.
5. Silvera SS, Aidi HE, Rudd JH, Mani V, Yang L, Farkouh M, Fuster V, Fayad ZA. Multimodality imaging of atherosclerotic plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral arteries. Atherosclerosis. 2009;207:139 -143.
6. Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong C, Rafique A, Hargeaves R, Farkouh M, Fuster V, Fayad ZA. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med. 2008;49:871- 878. (Pubitemid 351793426)
7. Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, Fuster V, Fayad ZA. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007; 50:892- 896. (Pubitemid 47268746)
8. Subramanian S, Tawakol A, Burdo TH, Abbara S, Wei J, Vijayakumar J, Corsini E, Abdelbaky A, Zanni MV, Hoffmann U, Williams KC, Lo J, Grinspoon SK. Arterial inflammation in patients with HIV. JAMA. 2012; 308:379 -386.
9. Fifer KM, Qadir S, Subramanian S, Vijayakumar J, Figueroa AL, Truong QA, Hoffmann U, Brady TJ, Tawakol A. Positron emission tomography measurement of periodontal (18)f-fluorodeoxyglucose uptake is associated with histologically determined carotid plaque inflammation. J Am Coll Cardiol. 2011;57:971-976. (Correction. 2011;57:1717.)
10. Rogers IS, Nasir K, Figueroa AL, Cury RC, Hoffmann U, Vermylen DA, Brady TJ, Tawakol A. Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. J Am Coll Cardiol Cardiovasc Imaging. 2010;3:388 -397.
11. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, Yates D, LaMuraglia GM, Furie K, Houser S, Gewirtz H, Muller JE, Brady TJ, Fischman AJ. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48:1818 -1824. (Pubitemid 44648622)
12. Wenning C, Stegger L, Hermann S, Schober O, Schaófers M. F-18-FDG imaging for atherosclerotic plaque characterization. Curr Cardiovasc Imaging Rep. 2011;4:190 -198.
13. Folco EJ, Sheikine Y, Rocha VZ, Christen T, Shvartz E, Sukhova GK, Di Carli MF, Libby P. Hypoxia but not inflammation augments glucose uptake in human macrophages: implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucosepositron emission tomography. J Am Coll Cardiol. 2011;58:603-614.
14. Yun M, Jang S, Cucchiara A, Newberg AB, Alavi A. 18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. Semin Nucl Med. 2002;32:70 -76. (Pubitemid 34112944)
15. Kim TN, Kim S, Yang SJ, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Vascular inflammation in patients with impaired glucose tolerance and type 2 diabetes: analysis with18F-fluorodeoxyglucose positron emission tomography. Circ Cardiovasc Imaging. 2010;3:142-148.
16. Yang SJ, Kim S, Hwang SY, Kim TN, Choi HY, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Association between sRAGE, esRAGE levels and vascular inflammation: analysis with (18)Ffluorodeoxyglucose positron emission tomography. Atherosclerosis. 2012;220:402- 406.
17. Tahara N, Kai H, Yamagishi S, Mizoguchi M, Nakaura H, Ishibashi M, Kaida H, Baba K, Hayabuchi N, Imaizumi T. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol. 2007;49: 1533-1539. (Pubitemid 46517964)
18. Figueroa AL, Subramanian SS, Cury RC, Truong QA, Gardecki JA, Tearney GJ, Hoffmann U, Brady TJ, Tawakol A. Distribution of inflammation within carotid atherosclerotic plaques with high-risk morphological features: a comparison between positron emission tomography activity, plaque morphology, and histopathology. Circ Cardiovasc Imaging. 2012;5:69 -77.
19. Bucerius J, Mani V, Moncrieff C, Rudd JH, Machac J, Fuster V, Farkouh ME, Fayad ZA. Impact of noninsulin dependent type 2 diabetes on carotid wall 18F-fluorodeoxyglucose positron emission tomography uptake. J Am Coll Cardiol. 2012;59:2080 -2088.
20. Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, Nikolaou K, Reiser MF, Bartenstein P, Hacker M. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med. 2009;50: 1611-1620.
21. Fayad ZA, Mani V, Woodward M, Kallend D, Bansilal S, Pozza J, Burgess T, Fuster V, Rudd JH, Tawakol A, Farkouh ME. Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Am Heart J. 2011;162:214-221.
22. Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, Fuster V, Ballantyne CM, Stein EA, Tardif JC, Rudd JH, Farkouh ME, Tawakol A. dal-PLAQUE Investigators. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomized clinical trial. Lancet. 2011;378: 1547-1559.
23. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, Hayabuchi N, Imaizumi T. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006;48:1825-1831. (Pubitemid 44648621)
24. Maóki-Petaójaó KM, Elkhawad M, Cheriyan J, Joshi FR, Oóstoór AJK, Hall FC, Rudd JHF, PhD, Wilkinson IB. Anti-tumour necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation. 2012;126:2473-2480.
25. Gravallese EM, Corson JM, Coblyn JS, Pinkus GS, Weinblatt ME. Rheumatoid aortitis: a rarely recognized but clinically significant entity. Medicine (Baltimore). 1989;68:95-106. (Pubitemid 19088085)
26. Greenberg JD, Furer V, Farkouh ME. Cardiovascular safety of biologic therapies for the treatment of RA. Nat Rev Rheumatol. 2011; 8:13-21.
27. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, Bridges SL Jr, Zhang J, McVie T, Howard G, van der Heijde D, Cofield SS. TEAR Investigators. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum. 2012;64: 2824-2835.